Financial Performance - The company's operating revenue for 2022 was ¥244,813,144.24, a decrease of 48.28% compared to ¥473,336,155.34 in 2021[23]. - The net profit attributable to shareholders for 2022 was -¥184,656,511.85, representing a decline of 752.60% from ¥28,295,675.93 in 2021[23]. - The net cash flow from operating activities was ¥4,374,452.23, down 93.83% from ¥70,856,510.64 in the previous year[23]. - The total assets at the end of 2022 were ¥1,534,759,509.42, a decrease of 3.17% from ¥1,585,013,039.67 at the end of 2021[23]. - The company's net assets attributable to shareholders decreased by 23.74% to ¥587,546,315.46 from ¥770,486,831.33 in 2021[23]. - The basic earnings per share for 2022 was -¥0.61, a decline of 777.78% compared to ¥0.09 in 2021[23]. - The weighted average return on equity was -27.19% in 2022, down 30.93% from 3.74% in 2021[23]. - The company reported a total of ¥4,053,714.32 in non-recurring gains and losses for 2022, compared to ¥22,326,810.29 in 2021[30]. - The company's financial expenses increased by 42.54% in 2022, amounting to ¥43,188,687.42, primarily due to increased shareholder loans and subsidiary interest expenses[66]. Operational Challenges - The company's performance declined due to external environmental fluctuations, resulting in decreased production line operating rates and delivery delays[4]. - Major raw material prices increased significantly, leading to a decrease in membrane product gross profit by RMB 23.04 million compared to the same period last year[4]. - The gross profit from membrane engineering decreased by RMB 78.83 million year-on-year due to reduced new and ongoing engineering projects and provisions for litigation liabilities[4]. - Credit impairment losses increased by RMB 43.56 million, primarily due to provisions for overdue accounts receivable[4]. - Asset impairment losses rose by RMB 15.88 million, mainly from provisions for engineering project asset impairments[4]. - Other income decreased by RMB 7.01 million due to lower amortization of government subsidies for research projects[5]. - The company faced significant challenges due to external economic fluctuations, resulting in production line downtime and increased raw material costs[51]. Strategic Focus and Future Plans - The company plans to maintain its focus on membrane products and technology services, aiming to enhance revenue and performance as external conditions improve in 2023[5]. - The company aims to achieve a national environmental equipment manufacturing industry output value of 1.3 trillion yuan by 2025, focusing on membrane technology as a key direction[36]. - The company is involved in providing wastewater treatment operation and technical services, primarily to government agencies and municipal units[45]. - The company is exploring opportunities for mergers and acquisitions to strengthen its market position[57]. - The company aims to improve its market share by enhancing product quality and developing innovative membrane technologies[69]. - The company plans to invest in new product and process development, technology upgrades, and market expansion in 2023, leveraging cash flow and financing[100]. Research and Development - The company has made significant breakthroughs in membrane material improvement, product research and development, and application of membrane technology processes during the reporting period[47]. - The company applied for 17 patents, with 6 patents granted, and received multiple national-level research project completions[47]. - The company is focused on enhancing its technological capabilities through research and development initiatives[57]. - In 2022, the company's R&D investment amounted to ¥24,089,784.21, representing 9.84% of operating revenue, an increase from 5.93% in 2021[71]. - The company has developed a new low-cost, high-performance PVDF modified membrane with independent intellectual property rights, significantly reducing investment and operating costs for membrane separation applications[69]. Governance and Management - The company is committed to maintaining a governance structure that complies with relevant laws and regulations to ensure transparency and protect shareholder interests[112]. - The company established a performance evaluation and incentive mechanism for senior management, aligning with its development status[119]. - The company reported a change in senior management, with the resignation of key personnel including the chief scientist and deputy general manager[126]. - The company has a significant focus on R&D, with a new Chief Scientist appointed to enhance technological advancements[128]. - The company is committed to maintaining a strong leadership structure to support its growth and market expansion strategies[128]. Environmental Compliance - The company achieved a COD discharge concentration of 21.6 mg/L, significantly below the regulatory limit of 50 mg/L, with a total COD discharge of 1,033 tons[183]. - The company reported a total nitrogen (TN) discharge of 10.6 mg/L, which is also below the regulatory limit of 15 mg/L, with a total TN discharge of 518 tons[183]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[189]. - The company has committed to increasing the use of renewable energy by replacing traditional lighting with solar-powered LED lights[189]. - The company has established emergency response plans for environmental incidents, which have been filed with local environmental authorities[185].

天津膜天膜科技股份有限公司（以下简称"公司"）已于2023年4月19日发 布了《2022年年度报告及摘要》。为便于广大投资者更深入全面地了解公司情况， 公司定于2023年5月8日（星期一）下午15:00-17:00举行2022年度网上业绩说明 会，现将有关事项通知如下：本次2022年度网上业绩说明会将采用网络远程的方 式举行，投资者可登陆"全景路演天下"（http://rs.p5w.net）参与本次业绩 说明会。出席本次年度报告说明会的人员有：公司董事长兼总经理范宁先生、副 总经理/投融资总监/董事会秘书宋辉鹏先生、副总经理/财务总监于建华先生、 独立董事王春青先生。 为提高交流效率，公司现提前向投资者征集相关问题，广泛听取投资者的意 见和建议。投资者可于2023年5月7日（星期日）17:00 时前将有关问题通过电子 邮件的形式发送至公司投资者关系邮箱（ir@motimo.com.cn）。欢迎广大投资者 积极参与！ 证券代码：300334 证券简称：津膜科技 公告编码：2023-033 天津膜天膜科技股份有限公司 关于举行2022年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完 ...

编号：2015-001 证券代码：300334 证券简称：津膜科技 天津膜天膜科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------------|-------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 □分析师会议 | | | 类别 | □媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 深圳市尊道投资有限公司 张应涛 | | | 人员姓名 | 国寿投资控股有限公司 吴雅婧 | | | | 民生证券 王宁 | | | | 信诚资本 魏华 | | | | 银河证券 邹序元 | | | | 银河证券 蒋昕昊 | | | 时间 | 2015 年 12 月 15 | 10:00-11:00 | | 地点 | 天津市河西区解放南路 | 256 号泰达大厦 18 层会议室 ...

编号：2016-001 证券代码：300334 证券简称：津膜科技 天津膜天膜科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|---------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 安信证券 杨心成、邵琳琳 | | | 人员姓名 | 广发证券 邱长伟 | | | | 工银瑞信 孙楠 | | | | 上海沣杨资产 张楠 | | | | 英大资产 郭元庆 | | | | 博道投资 陈子木 | | | | 国都基金 张小强 | | | | 聚睿投资 汲亚飞 | | | | 国寿养老 黄锦超 | | | | 上海泓湖 邢达 | | | | 方正自营 卫子清 | | | | 深圳景泰利丰投资 刘虓虓 | | | ...

编号：2017-001 证券代码：300334 证券简称：津膜科技 天津膜天膜科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 东兴证券 庞天一 | | | 人员姓名 | 华泰证券 徐科 | | | | 光大证券 魏天野 | | | 时间 | 2017 年 1 月 | 14:00-15:00 | | 地点 | 天津市河西区解放南路 | 256 号泰达大厦 18 层 | | 上市公司接待人 | 副总经理兼董事会秘书 郝锴 | | | 员姓名 | | | | 投资者关系活动 | 一、互动问答 | | | ...

证券代码：300334 证券简称：津膜科技 编号：2017-002 天津膜天膜科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------------|---------------------------------------------| | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 北京中环膜材料科技有限公司 张江英 | | | 人员姓名 | | 中国水务投资有限公司 汤德勤、赵海波、吕君为 | | | 东旭蓝天新能源股份有限公司 游跃 | | | | E20 环境平台 李斯 | | | | 山西证券 赵腾辉、张婉姝 | | | | 久期投资 黄征宇 | | | | 深圳市大岩资产管理有限公司 陈樟 | | | | | 中金公司 张钰淇、戚政韬、雒文 | | ...

Financial Performance - The company's revenue for Q3 2022 was ¥64,720,522.74, a decrease of 39.79% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥14,788,940.24, representing a decline of 463.97% year-on-year[5]. - The basic earnings per share were -¥0.05, down 600.00% from the previous year[5]. - Total operating revenue for Q3 2022 was ¥183,783,314.31, a decrease of 41.8% compared to ¥315,695,885.10 in Q3 2021[29]. - Operating profit for Q3 2022 was -¥38,492,173.12, compared to a profit of ¥20,635,400.94 in Q3 2021, indicating a significant decline[29]. - The net profit for Q3 2022 was -42,798,505.90 CNY, compared to a net profit of 19,067,671.70 CNY in the same period last year, indicating a significant decline[30]. - The company's total comprehensive income for the period was -42,798,505.90 CNY, compared to 19,067,671.70 CNY in the same period last year[30]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,549,438,051.99, a decrease of 2.24% from the end of the previous year[5]. - Non-current assets totaled ¥1,028,238,267.17, down from ¥1,052,334,148.70, a decrease of 2.3%[26]. - The company's total assets decreased to ¥1,549,438,051.99 from ¥1,585,013,039.67, reflecting a decline of 2.2%[27]. - Total current liabilities rose to ¥631,800,736.74 from ¥620,135,622.33, an increase of 2.7%[27]. - Total liabilities amounted to ¥747,106,292.88, slightly up from ¥746,145,102.04, indicating a marginal increase[27]. Cash Flow - The net cash flow from operating activities was 26,049,876.43 CNY, compared to 41,902,090.62 CNY in the previous year, representing a decline of about 37.8%[31]. - The company reported a cash and cash equivalents balance of 39,659,067.78 CNY at the end of the period, down from 70,974,136.89 CNY at the beginning of the period, a decrease of approximately 44%[32]. - The company incurred a total of 262,110,228.91 CNY in cash outflows from financing activities, compared to 269,590,584.93 CNY in the previous year, showing a slight decrease of about 2.5%[32]. Operating Costs and Income - The company reported a significant drop in operating income, which decreased by ¥131,912,600.79, or 41.78%, primarily due to the exclusion of Zhejiang Jinmo from the consolidated scope and the impact of the pandemic[14][15]. - Operating costs also fell by 31.06% year-on-year, amounting to ¥141,816,763.89[14]. - Total operating costs for Q3 2022 were ¥237,831,084.77, down from ¥304,115,686.58 in the same period last year, reflecting a reduction of 21.7%[29]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,753[18]. - The largest shareholder, Tianjin Membrane Engineering Technology Co., Ltd., holds 21.19% of shares, totaling 64,004,465 shares[18]. - The second-largest shareholder, Hua Yi Technology International, holds 10.40% of shares, totaling 31,409,000 shares[18]. - The top ten shareholders hold a significant portion of the company's shares, with the top three alone accounting for over 41%[18]. Legal and Regulatory Matters - The company is involved in a lawsuit regarding a sewage treatment project with a claim amount of RMB 17,977,994.12[22]. - The company has received an arbitration request for payment related to two engineering projects, including interest[21]. Future Plans and Investments - The company plans to provide a guarantee of RMB 450 million for its subsidiaries' financing needs over the next twelve months[20]. - High-tech Investment Development Co., Ltd. plans to reduce its holdings by up to 6,041,307 shares, representing 2% of the company's total share capital[23]. - The company has completed the transfer of actual control to the new management team as per the investment agreement[23].

证券代码：300334 证券简称：津膜科技 公告编码：2022-075 天津膜天膜科技股份有限公司 关于参加2022年度天津辖区上市公司半年报业绩说明会 与投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 为加强与广大投资者的交流沟通，天津膜天膜科技股份有限公司（以下简称 "公司"）定于2022年9月6日（周二）13:40-16:40 参加由天津证监局主办、天津 上市公司协会与深圳市全景网络有限公司协办的"2022年度天津辖区上市公司半 年报业绩说明会与投资者网上集体接待日"活动，本次活动将采用网络远程的方 式举行，投资者可登录"全景路演"（ http://rs.p5w.net）参与本次互动交流。 网上互动交流时间为 2022 年 9 月 6 日（星期二）下午 15:00-16:30。 出席本次"2022 年度天津辖区上市公司半年报业绩说明会与投资者网上集 体接待日"活动的人员有：公司董事长兼总经理范宁先生，副总经理兼董事会秘 书展树华先生，副总经理兼财务总监于建华先生。欢迎广大投资者积极参与。 特此公告！ 天津膜天膜科技股份有限 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥119,062,791.57, a decrease of 42.81% compared to ¥208,197,972.20 in the same period last year[19]. - The net profit attributable to shareholders was -¥26,698,811.20, representing a decline of 371.57% from ¥9,831,374.05 in the previous year[19]. - The net cash flow from operating activities was ¥9,020,260.35, down 80.01% from ¥45,130,776.94 in the same period last year[19]. - The basic and diluted earnings per share were both -¥0.088, a decrease of 366.67% compared to ¥0.033 in the previous year[19]. - Total assets at the end of the reporting period were ¥1,556,511,147.53, a decrease of 1.80% from ¥1,585,013,039.67 at the end of the previous year[19]. - The net assets attributable to shareholders decreased by 3.47% to ¥743,788,020.13 from ¥770,486,831.33 at the end of the previous year[19]. - The company reported a total revenue of 1,504,648.17 yuan, reflecting a decrease of 5.85% compared to the previous period[42]. - The company reported a net loss of CNY 663,227,420.82, compared to a loss of CNY 636,528,609.62 in the previous period[178]. - The total comprehensive income for the first half of 2022 was a loss of CNY 26,476,879.94, compared to a profit of CNY 13,935,925.20 in the same period of 2021[185]. Revenue and Cost Management - Operating costs decreased by 27.86% to ¥92,798,104.78 from ¥128,629,469.09 in the previous year, reflecting improved cost management[36]. - Research and development expenses were ¥10,276,694.16, down 29.30% from ¥14,535,149.07, indicating a strategic focus on cost control amid revenue decline[36]. - The gross profit margin for specialized equipment manufacturing was 22.06%, a decrease of 16.16% compared to the previous year, reflecting the challenges in maintaining profitability amid declining revenues[38]. - The company's total investment during the reporting period was ¥4,774,773.96, a decrease of 80.45% compared to ¥24,422,601.05 in the same period last year[48]. - The company aims to reduce operational costs by 10% through efficiency improvements in the supply chain[102]. Market Position and Strategy - The company is primarily engaged in the R&D, production, and sales of ultrafiltration and microfiltration membranes and components, providing comprehensive solutions for water resource management[27]. - The company is facing intensified competition in the membrane product market, prompting a strategic shift to enhance product sales and value-added services[59]. - The company has a rich experience in project implementation across various sectors, including municipal, dyeing, petrochemical, and seawater desalination, which strengthens its market position[33]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by the end of 2023[101]. - A strategic acquisition of a local competitor is in progress, which is anticipated to increase the company's production capacity by 30%[102]. Research and Development - The company has established a strong R&D capability, supported by national key laboratories and various engineering design qualifications, enhancing its competitive edge in the membrane industry[32]. - The company plans to invest 200 million RMB in R&D for new technologies over the next two years[100]. - New product development includes the launch of a next-generation membrane technology expected to enhance efficiency by 10%[100]. - The company is exploring partnerships with international firms to leverage technology and expand its global footprint[109]. Environmental Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[72]. - The company reported a total suspended solids discharge of 0.34 tons, with a concentration of 12 mg/L, compliant with discharge standards[72]. - The company has completed the construction of pollution prevention facilities, including various treatment pools and biological reaction pools, with stable compliance achieved[74]. - The company has implemented energy-saving measures, including replacing 20 streetlights with solar-powered lights and upgrading to LED lighting, which improves energy efficiency[80]. - The company has not faced any administrative penalties for environmental issues during the reporting period[79]. Governance and Compliance - The company has conducted several shareholder meetings, with participation rates ranging from 21.26% to 43.36%, ensuring stakeholder engagement in corporate governance[65]. - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from capital reserves for the half-year period[68]. - The company has committed to ensuring that it does not harm the interests of the listed company and its minority shareholders during the period of holding shares[90]. - The company has established a commitment to maintain effective communication and information disclosure regarding related party transactions[94]. - The company is focused on enhancing its governance structure to ensure compliance with related party transaction regulations[93]. Legal Matters - The company is currently involved in another lawsuit with a claim amount of 20.881 million yuan, which is still under trial in the Hebei Province Intermediate People's Court[120]. - The company has faced delays in payment from the defendant, leading to multiple legal actions to recover owed amounts[120]. - The company is awaiting the final judgment on the ongoing lawsuits, which may impact its future profits[120]. - The company is involved in a legal dispute with Tianjin Water Supply Construction Co., seeking payment of construction fees totaling CNY 270 million and interest, amounting to a total claim of CNY 297.69 million[123]. Future Outlook - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 20% to 30% based on current market trends and demand[102]. - The company has outlined a positive outlook for the future, projecting a revenue growth of 25% for the next fiscal year[105]. - The company plans to enhance its market expansion strategies and invest in new product development[198]. - The company has set a performance guidance for the next quarter, expecting a revenue growth of 10% year-over-year[200].